Shandong Tumor Hospital
12
4
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Role: lead
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
Role: lead
Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer
Role: lead
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Role: collaborator
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
Role: collaborator
Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma
Role: collaborator
Therapeutic Drug Monitoring of Teicoplanin in Children
Role: collaborator
Radiomics of Immunotherapeutics Response Evaluation and Prediction
Role: collaborator
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
Role: collaborator
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
Role: collaborator
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Role: collaborator
TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
Role: collaborator
All 12 trials loaded